MedTrace Logo

A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105

NCT06432647 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-01-23

No results posted yet for this study

Summary

The goal of this Phase 1 interventional study is to assess the safety, tolerability and pharmacokinetics of ATH-1105 in healthy male and female participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ATH-1105

ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.

DRUG

Placebo

Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.

Sponsors & Collaborators

  • Fortrea Holdings, Inc.

    collaborator UNKNOWN

  • Athira Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-24
Primary Completion
2024-11-25
Completion
2024-11-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06432647 on ClinicalTrials.gov